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Background and Purpose  Perampanel is the first α-amino-3-hydroxy-5-methyl-4-isoxazole-
propionic acid (AMPA)-receptor antagonist developed to treat epilepsy. The effects of either 
rapid or slow dose titration on adverse events remain to be elucidated.
Methods  Eighty-five patients received perampanel between March 2016 and August 2016. 
Patients were divided into two groups according to their dosing schedule: rapid dose titration 
(2-mg increments at intervals of 1 to 2 weeks) and slow dose titration (2-mg increments at in-
tervals of at least 3 weeks). Seizure frequency and adverse events were analyzed over 3 months.
Results  Adverse events were reported by 47 (58%) of the 81 patients analyzed, with 12 (15%) 
patients discontinuing perampanel due to adverse events. Common adverse events included 
dizziness (n=30, 37%), aggressive mood and behavior (n=19, 24%), gait disturbance (n=16, 
20%), and sleep problems (n=10, 12.4%). The overall adverse events were similar in the slow-ti-
tration group (38 of 61 patients) and the rapid-titration group (8 of 20 patients, p=0.081). How-
ever, none of the 20 patients in the slow-titration group experienced gait disturbance, compared 
with 16 of the 61 patients in the rapid-titration group (p=0.009), while appetite change was ex-
perienced by 4 patients in the slow-titration group but only 1 in the rapid-titration group 
(p=0.003). No relationship was noted between adverse events and the maximum dose of per-
ampanel (p=0.116). Sex differences were observed, with the response to perampanel being bet-
ter and the rate of adverse events being higher in females (p=0.015 and p=0.046, respectively).
Conclusions  Slow titration of perampanel may reduce perampanel-related adverse events.
Key Words   perampanel, drug-resistant epilepsy, antiepileptic drug, 
α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid.
Adverse Events During Perampanel Adjunctive Therapy 
in Intractable Epilepsy
INTRODUCTION
The new antiepileptic drug (AED) perampanel is an antagonist to the α-amino-3-hydroxy-
5-methyl-4-isoxazole-propionic acid (AMPA)-type glutamate receptor. Perampanel inhib-
its the generation and spread of epileptiform activity at postsynaptic excitatory synapses by 
blocking AMPA receptors.1 Several prospective and retrospective studies have investigated 
the efficacy of perampanel as an adjunctive AED for epilepsy.2-10 Overall 42–50% of the 
patients in these previous studies with drug-resistant epilepsy found that perampanel de-
creased the frequency of seizures by at least 50%.5-10 However, unexpected adverse events 
such as gait disturbance and aggressive behavior have been reported. Several experts have 
recommended applying slow dose titration of perampanel in order to reduce adverse events, 
but there are few data supporting this recommendation.2,8,9,11 
In the present study we investigated the effects of rapid and slow dose titration on the fre-
quency of adverse events when taking perampanel.
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METHODS
We reviewed patients who started taking perampanel as an 
adjunctive therapy from March 1 to August 31, 2016 at Sev-
erance Children’s Hospital in Korea. All patients were aged 
12 years or older and experienced focal seizures classified 
according to the 2017 International League Against Epilepsy 
Classification of Epileptic Seizures.12
Patients included in the study had drug-resistant epilepsy, 
meaning uncontrolled seizures despite taking more than two 
appropriate AEDs, and a minimum (min) follow-up period 
of 3 months. Patients who had incomplete data were excluded, 
as were those with coexisting undistinguishable nonepilep-
tic events from seizures. This study was approved by the Insti-
tutional Review Board of Severance Hospital (IRB No. 4-2016-
0684). 
For the analysis, patients who underwent titration of 2-mg 
increments at intervals of 1 to 2 weeks were categorized into 
the rapid-titration group, while those who underwent titra-
tion at intervals of 3 weeks or longer were categorized into 
the slow-titration group. Perampanel was titrated from a dai-
ly dose of 2 mg at bedtime. For some patients who took en-
zyme-inducing AEDs, including phenytoin, carbamazepine, 
or oxcarbazepine, perampanel was started at 4 mg and then 
increased in increments of 2 mg daily at intervals of 1 week. 
The perampanel dose or titration was scheduled on an indi-
vidual basis for all patients at the discretion of the physician 
in charge. The number of concomitant medications, charac-
teristics of the patients and their caregivers, tolerability, and 
adverse events were considered. Dose titration was stopped 
if either seizure freedom was achieved or further dose titra-
tion was not tolerated. 
Adverse events and the discontinuation rate during the ini-
tial 3 months of perampanel treatment were collected. Physi-
cians specifically asked the patients about the presence of 
known perampanel-related adverse events, including gait dis-
turbance, ataxia, dizziness, lethargy, appetite change, weight 
change, sleep change, mood change, aggressive behavior, 
slurred speech, and confusion. 
To assess efficacy, the monthly seizure frequency measured 
immediately before the initiation of perampanel was com-
pared to that during the third month of perampanel treat-
ment. Patients or caregivers counted seizures at home, and 
reported their seizure frequency at each visit. Seizure inten-
sity was not measured. Before the initiation of perampanel, 
seizure types and baseline seizure frequency were reviewed 
and clarified with caregivers and patients. Responders were 
defined as persons exhibiting a reduction in monthly seizure 
frequency of at least 50% compared to the baseline frequency. 
Data were also collected by reviewing medical charts. The 
age at seizure onset, epilepsy syndrome, etiology, seizure 
type, medical history, past AED history, level of cognition, 
surgery history, and ketogenic diet history were reviewed. 
Intellectual disability was defined as significant limitations in 
both intellectual functioning and adaptive behavior.13 Limita-
tion of intellectual functioning was defined as an intelligence 
quotient of less than 70. Brain MRI and electroencephalog-
raphy results were also reviewed. The perampanel use was 
quantified by recording the dose at each visit, the titration 
schedule, the seizure frequency at each visit, the dose at the 
time of adverse events, and the maximum (max) dose. Rea-
sons for the discontinuation of perampanel and the time when 
this happened were collected. 
Statistical analyses
All statistical analyses were performed using IBM SPSS Sta-
tistics (version 23.0, IBM Corp., Armonk, NY, USA). Nor-
mally distributed continuous variables were summarized as 
mean±standard-deviation values and analyzed using Stu-
dent’s t-test. Nonparametric continuous variables are expressed 
as median: max, min, interquartile range (IQR) values, and 
were analyzed using either the Mann-Whitney U test or the 
Kruskal-Wallis test. The chi-square test and Fisher’s exact test 
were applied to categorical variables. Differences in seizure fre-
quency over 3 months were analyzed using the Wilcoxon 
signed-rank test. Ordinal variables were analyzed using either 
the Mantel-Haenszel chi-square test or a mixed linear model. 
A probability value of p<0.05 was considered statistically sig-
nificant. 
RESULTS
Demographics 
Four of 85 patients who received perampanel with a min fol-
low-up of 3 months were excluded due to insufficient seizure 
data, and so 81 patients were finally included in the assessment. 
Males comprised 44 of the 81 patients. The median age of 
the patients was 17 years (max=32 years, min=12 years, IQR= 
14–20 years). The median follow-up duration was 3 months 
(max=6 months, min=3 months, IQR=3–4 months). MRI 
revealed lesions related to epilepsy in 45 (55.6%) patients: 
common etiologies included malformations of cortical de-
velopment (n=17, 21.0%), hypoxic ischemic encephalopa-
thy (n=11, 13.6%), and infection (n=10, 12.4%), followed 
by genetic or metabolic etiologies (n=9, 11.1%), and trauma 
(n=3, 3.7%). All patients had drug-resistant epilepsy, and 
the median number of concomitant AEDs was 3 (max=6, 
min=1, IQR=3–4). Many patients had consumed a keto-
genic diet (n=33, 40.7%) or received epilepsy surgery (n=36, 
44.4%) including vagal nerve stimulation (n=19, 23.5%), high-
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lighting the intractability of their seizures. Twenty (24.7%) of 
the 81 patients used carbamazepine, oxcarbazepine, and/or 
phenytoin concomitantly, while 57 (85.1%) of the 67 patients 
with available data had intellectual disability (Table 1). 
Adverse events and related factors 
Overall, 47 (58.0%) patients reported adverse events, with 
30 (37.0%) experiencing more than two adverse events. The 
most-common adverse events were dizziness and somno-
lence (n=30, 37.0%), followed by aggressive mood and be-
havior (n=19, 23.5%) and gait disturbance (n=16, 19.8%). 
Sleep problems (n=10, 12.4%), appetite change (n=6, 7.4%), 
weight change (n=3, 3.7%), and confused or slurred speech 
(n=3, 3.7%) were also common (Fig. 1). Other adverse events 
included excessive sputum production, drooling, dysphagia, 
nausea, memory impairment, and bizarre feeling. 
There were no significant differences between rapid titra-
tion and slow titration in the overall occurrence of adverse 
events events (38 of 61 patients vs. 8 of 20 patients, p=0.081), 
withdrawal rates of perampanel (16 of 61 patients vs. 4 of 20 
patients, p=0.575), and reasons for early withdrawal (p=0.155). 
However, gait disturbance was reported more frequently in 
the rapid-titration group than in the slow-titration group (16 
of 61 patients vs. 0 of 20 patients, p=0.009), while appetite 
change occurred less in the former group (1 of 61 patients vs. 
4 of 20 patients, p=0.003). The occurrence of dizziness, weight 
change, sleep change, behavior change, and slurred speech 
did not differ between the two groups (Table 2). 
Experiencing or not experiencing adverse events did not 
affect the use of enzyme-inducing AEDs (13 of 47 patients vs. 
7 of 34 patients, p=0.603), max dose of perampanel [8 (max= 
Table 1. Demographic variables of the 81 patients
Variable Value
Sex, male 44 (54.3)
Adolescents* 53 (65.4)
Age, years 17 (32, 12, 14–20)
Body weight, kg 54.3±19.5
Age at onset of seizures, years (n=79) 4 (15, 0, 1–8)
Presence of lesion on MRI 45 (55.6)
Previous ketogenic diet 33 (40.7)
Previous epilepsy surgery 36 (44.4)
Previous vagal nerve stimulation surgery 19 (23.5)
Intellectual disability (n=67) 57 (85.1)
Type of seizures 
Focal seizures 81 (100)
Focal to bilateral tonic-clonic seizures 48 (59.3)
Others† 44 (54.3)
History of IS or LGS 37 (45.7)
Number of concomitant AEDs 3 (6, 1, 3–4)
Concomitant use of CBZ, PHT, or OXC 20 (24.7)
Initial EEG‡
Normal 3 (3.7)
Abnormal background only 7 (8.6)
Focal slowing or epileptiform discharges 42 (51.9)
Multifocal epileptiform discharges 29 (35.8)
Data are median (maximum, minimum, interquartile range), mean± stan-
dard-deviation, or n (%) values. 
*Up to 18-years-old, †Epileptic spasm (n=11), atypical absence (n=10), 
drop attacks (n=8), eyelid myoclonus (n=4), or tonic seizure (n=24); 15 
patients had multiple seizure types, ‡EEG immediately before adminis-
tering perampanel. 
AED: antiepileptic drug, CBZ: carbamazepine, IS: infantile spasms, LGS: 
Lennox-Gastaut syndrome, OXC: oxcarbazepine, PHT: phenytoin.
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Fig. 1. Numbers of patients who experienced adverse events. The most-common adverse events were dizziness and somnolence, followed by ag-
gressive mood and behavior. Other adverse events included excessive sputum production, drooling, dysphagia, nausea, memory impairment, and 
bizarre feeling.
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12, min=2, IQR=8–10) vs. 10 (max=12, min=6, IQR=8–12), 
p=0.116], or number of concomitant AEDs [4 (max=5, min= 
1, IQR=3–4) vs. 3 (max=6, min=2, IQR=3–5), p=0.502]. 
However, more than half of the patients who experienced 
adverse events were female, while only 32.4% of the patients 
who did not experience adverse events were female, indicating 
a significant sex difference (26 of 47 patients vs. 11 of 34 pa-
tients, p=0.046) (Table 3). 
Adverse events subsided in 89.4% (n=42) of the patients. 
Of 47 who reported adverse events, 25 patients received an 
intervention and 23 experienced resolution. The interven-
tions included discontinuation of perampanel (n=15), re-
duction of perampanel (n=9), and reduction of other drugs 
(n=1). Overall, 20 patients (24.7%) discontinued peram-
panel within 3 months: 12 (14.8%) withdrew early due to 
adverse events including gait disturbance (n=5, 6.2%), dizzi-
ness (n=5, 6.2%), and aggressive mood and behavior (n=2, 
2.5%), and 8 (9.9%) withdrew early due to ineffectiveness. 
Five patients unexpectedly stopped taking perampanel at 
low doses (e.g., 2 or 4 mg) due to adverse events. Only one pa-
tient stopped perampanel at 12 mg. Two patients who stopped 
at 2 mg experienced severe dizziness, and three patients who 
stopped at 4 mg reported experiencing multiple side effects 
including gait disturbance, dizziness, and aggressive behav-
ior (Fig. 2). 
Efficacy 
The median baseline monthly seizure frequency was 13 (max= 
900, min=1, IQR=5–90), and this reduced to 8 after 3 months 
of perampanel use (max=300, min=0, IQR=2–70) (p<0.001). 
Table 2. Comparison of fast titration (2-mg increments at intervals of 1 to 2 weeks) and slow titration (2-mg increments at intervals of 3 weeks 
or longer)
Fast titration (n=61) Slow titration (n=20) p
Adverse events 38 (62.3) 8 (40.0) 0.081
Early withdrawal of perampanel 16 (26.2) 4 (20.0) 0.575
Reason for withdrawal
Adverse events 11 (18.0) 1 (5.0) 0.155
Ineffectiveness 5 (8.2) 3 (15.0)
Adverse events 
Gait disturbance 16 (26.2) 0 (20.0) 0.009
Dizziness 23 (37.7) 4 (20.0) 0.145
Appetite change 1 (1.6) 4 (20.0) 0.003
Weight change 3 (4.9)  0 0.571
Sleep disturbance 6 (9.8) 4 (20.0) 0.210
Aggressiveness or mood change 15 (24.6) 2 (10.0) 0.164
Slurred or confused speech 2 (3.3) 1 (5.0) 0.724
Others* 4 (6.6) 2 (10.0) 0.610
Data are n (%) values. 
*Others include hypersalivation, dysphagia, nausea, memory impairment, and bizarre feeling. 
Table 3. Comparison between patients who experienced and did not experience adverse events
Adverse events (n=47) No adverse events (n=34) p
Sex, female 26 (55.3) 11 (32.4) 0.046
Age at seizure onset, years 4 (15, 0, 1–8) 5 (13, 0, 1–8) 0.988
Adolescents* 29 (61.7) 24 (70.6) 0.482
Age, years 17 (32, 12, 14–22) 17 (24, 12, 14–20) 0.818
CBZ, PHT, or OXC use 13 (27.7) 7 (20.6) 0.603
Titration every week 6 (12.8) 5 (14.7) 0.653
Titration every 2 weeks 31 (66.0) 19 (55.9)
Titration every 3 weeks or longer 10 (21.3) 10 (29.4)
Maximum dose of perampanel, mg 8 (12, 2, 8–10) 10 (12, 6, 8–12) 0.116
Number of concomitant AEDs 4 (5, 1, 3–4) 3 (6, 2, 3–5) 0.502
Data are median (maximum, minimum, interquartile range) or n (%) values. 
*Up to 18 years old.
AED: antiepileptic drug, CBZ: carbamazepine, OXC: oxcarbazepine, PHT: phenytoin.
300  J Clin Neurol 2018;14(3):296-302
Perampanel Dose TitrationJCN
Eight (9.9%) of the 81 patients became seizure-free, while an 
additional 20 (24.7%) patients experienced a reduction in sei-
zure frequency of at least 50%. The overall responder rate was 
34.6% (28 of 81 patients). 
More patients in the responder group were female (18 of 
28 patients vs. 19 of 53 patients, p=0.015). The responder 
group had a younger age at seizure onset [2 years (max=11 
years, min=0 years, IQR=1–4 years) vs. 5 years (max=15 
years, min=0 years, IQR=2–10 years), p=0.002] and fewer 
concomitant AEDs [3 (max=5, min=1, IQR=2–4) vs. 4 
(max=6, min=2, IQR=3–5), p=0.005]. Age, body weight, 
type of seizures, baseline seizure frequency, and max dose of 
perampanel did not differ between the responder and nonre-
sponder groups. The number of patients who took enzyme-
inducing AEDs did not differ between responders and non-
responders (Table 4). 
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Fig. 2. Three-month seizure outcomes and occurrence of adverse events for different maximum doses of perampanel. A: The maximum doses 
were 2 and 4 mg in 7 patients. Two patients achieved seizure freedom when taking perampanel at the relatively low dose of 4 mg. The maximum 
doses were 6, 8, and 10 mg in more than two-thirds (56 of 81 patients) of patients. The rates of responders and seizure freedom were high for doses 
between 6 and 10 mg. The perampanel dose was increased to 12 mg when their seizures persisted, and no serious adverse events occurred. Howev-
er, the rates of responders and seizure freedom were significantly low at a dose of 12 mg. B: Five patients stopped taking perampanel at low doses 
(e.g., 2 or 4 mg) due to adverse events. Only one patient stopped taking perampanel at 12 mg. Two patients who stopped at a dose of 2 mg experi-
enced severe dizziness, and three patients who stopped at a dose of 4 mg reported experiencing multiple side effects including gait disturbance, 
dizziness, and aggressive behavior.
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The responder rates were high for doses between 6 and 10 
mg and low for a dose of 12 mg (Fig. 2). 
DISCUSSION
Several experts have suggested associations between ad-
verse events and rapid dose titration of perampanel,2,8,9,11 al-
though the supporting data have been sparse. The present 
study shows that gait instability-one of the common peram-
panel-related adverse events-may occur less often if the dose 
of perampanel is slowly escalated at intervals of 3 weeks or 
longer. This finding is supported by previous findings of sim-
ilar reductions in the occurrence of dizziness in the slow-ti-
tration group (>2 mg/2 weeks)8 and reduced falls among 
elderly patients with slower titration.14 It is particularly in-
terestingly that the serum level of perampanel takes 2 weeks 
to reach a steady state due to its long half-life.15
Reportedly 31% to 87% of patients experience adverse 
events when taking perampanel.2-10 Such a high frequency 
of adverse events might be due to AMPA receptors being 
widely distributed in the brain. In our study, 60% of the pa-
tients reported adverse events, but most of them resolved 
spontaneously or immediately after interventions, such as re-
ducing the perampanel dose. Only about 15% of our patients 
withdrew early due to adverse events. The slow dose titra-
tion that was used in our patients may have been responsible 
for the low withdrawal rates; in contrast, most previous clin-
ical trials and other real-world studies titrated perampanel 
rapidly and increased doses in 2-mg increments every 1 to 
2 weeks.2-10
One-third of our patients with drug-resistant epilepsy expe-
rienced benefits from perampanel, while one-tenth achieved 
seizure freedom. The patients who responded favorably to 
perampanel had a few characteristics that were similar: First, 
the responders comprised a higher percentage of female pa-
tients. Sex differences regarding drug responses have been 
reported for other AEDs, and lower glomerular filtration 
rates and lower body weight in females have been hypothe-
sized as underlying mechanisms.16 The clearance rate of 
perampanel is reportedly lower in females than in males,11 
possibly resulting in a higher serum concentration of peram-
panel in females for the same dose. A previous pooled-data 
study found that the response to perampanel was better in 
females.17 Second, the age at seizure onset was younger for 
responders than for nonresponders. Since this result has not 
been reported previously, it needs to be confirmed in future 
research. There may be differences in the nature of focal ep-
ilepsies between those with early and later onset. Although 
the efficacy of perampanel in children still needs to be inves-
tigated, this finding suggests that perampanel can play a spe-
cial role in tackling childhood epilepsies. 
With its short postmarketing period, the optimal adminis-
tration conditions of perampanel remain to be determined. 
In our study, similarly high rates of responders and seizure 
freedom were achieved with perampanel at doses of 6, 8, and 
10 mg. Doses of 2, 4, and 12 mg were less effective at reduc-
ing the rate of seizures. Most previous studies applied per-
ampanel at doses of 7–8 mg.5-9 The additional gain from ad-
ministering perampanel at the high dose of 12 mg remains 
controversial. Previous clinical trials found that responder 
Table 4. Comparison of responders (reduction in seizure frequency of ≥50%) and nonresponders
 Responders (n=28) Nonresponders (n=53) p
Sex, female 18 (64.3) 19 (35.8) 0.015
Age, years 17 (27, 12, 14–20) 17 (32, 12, 14–20) 0.226
Age at onset of seizures, years 2 (11, 0, 1–4) 5 (15, 0, 2–10) 0.002
Adolescents* (n=53) 21 (75.0) 32 (60.4) 0.188
Body weight, kg 52.3±15.5 55.2±21.2 0.517
Type of seizures
Focal to bilateral tonic-clonic seizures 16 (57.1) 32 (60.4) 0.778
Others 5 (17.9) 7 (13.2) 0.743
Cognitive impairment (n=67) 23/24 (95.8) 34/43 (79.1) 0.082
Concomitant AEDs 3 (5, 1, 2–4) 4 (6, 2, 3–5) 0.005
Concomitant use of CBZ, PHT, or OXC 7 (25.0) 13 (24.5) 0.963
Seizure frequency per month 
Baseline 10 (900, 1, 5–70) 30 (300, 1, 5–101) 0.618
After 3 months 1 (300, 0, 0–10) 27 (300, 0, 7–90) <0.001
Maximum dose of perampanel, mg 9 (12, 4, 8–10) 8 (12, 2, 6–12) 0.945
Data are median (maximum, minimum, interquartile range), mean±standard-deviation, or n (%) values. 
*Up to 18 years old. 
AED: antiepileptic drug, CBZ: carbamazepine, OXC: oxcarbazepine, PHT: phenytoin.
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rates were similar at doses of 12 and 8 mg, while some advo-
cated that the efficacy was higher at 12 mg.2-4
Some of the present patients seemed to respond dramati-
cally to low doses of perampanel, with two of them discon-
tinuing perampanel at 2 mg due to adverse events, while an-
other two patients achieved seizure freedom at 4 mg, which 
is inconsistent with the well-known dose dependency of per-
ampanel.15 Similar phenomena have been reported previous-
ly,6 and they might be due to the high variability in the serum 
concentration of perampanel between subjects.18 The clini-
cal characteristics in this patient group therefore need to be 
investigated further.
This study was subject to some limitations. First, the 3- 
month follow-up period was relatively short. However, since 
our patients experienced severe drug-resistant epilepsy and 
frequent seizures, we thought that 3 months was sufficient 
for determining the efficacy and tolerability of a newly added 
drug in most of our patients. Second, the serum perampanel 
concentration was not measured. There is a linear relation-
ship between the administered dose and plasma concentration 
of perampanel, and also between the plasma concentration of 
perampanel and its efficacy,15 although there may be inter-
individual variability. 
In conclusion, perampanel is a novel AED that is effective 
and safe for epilepsy. Although adverse events are common, 
some of them may be prevented by the slow titration of peram-
panel. 
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